|By PR Newswire||
|March 28, 2014 12:00 PM EDT||
BOWIE, Md., March 28, 2014 /PRNewswire/ -- Inovalon, Inc., a leading technology company providing advanced analytics and data-driven solutions to the healthcare industry, today announced medication quality performance measurement research to be presented at the Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo April 1–4 in Tampa, FL. The presentation will be Thursday, April 3rd at 11:30 am.
Inovalon will present on "Understanding the Rate Differential among Dual Eligible and Non-Dual Eligible Beneficiaries on the Star Quality Measure for Appropriate Treatment of Hypertension in Diabetes Patients." Inovalon's abstract was awarded the highest "GOLD" rating by a panel of AMCP editors with the help of 19 additional reviews, based on scores for relevance to managed care, bias, originality, clarity, and quality of the work.
The study was supported by data from Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®). The purpose was to further examine Centers for Medicare & Medicaid Services (CMS) Star Quality Measures for appropriate treatment of hypertension in diabetes between Dual Eligible (DE) and non-DE health plan members. Differences were found in the use of concurrent blood pressure medications, health services utilization, and prevalence of comorbid cardiovascular disorders between DE and non-DE members that may impact the quality measure rate. According to the study's authors, these differences indicate a need for further testing of this measure to assure it is a true measure of better quality of care and not a reflection of different characteristics and service utilization rates among DEs.
A prior study published by Inovalon, titled "The Impact of Dual Eligible Populations on CMS Five-Star Quality Measures and Member Outcomes in Medicare Advantage Health Plans," showed that DE members performed worse on 9 out of 10 key CMS Star Quality Measures and the only measure on which DEs performed better is one that examines use of recommended blood pressure medications in people with diabetes (Diabetes Treatment: BPD).
"Inovalon is harnessing the power of large longitudinal data using sophisticated statistical analytics to better understand differential performance on quality outcome measures at the member level," said Dan Rizzo, Chief Innovation Officer at Inovalon. "The goal of this research is to identify those factors contributing to consistently worse performance on clinical outcome measures among dual eligible beneficiaries to help guide interventions and policies aimed at improving care for this vulnerable population."
Inovalon's Statistical Research Team co-authors include: Sandhya Mehta, PhD; John F. Scoggins, PhD; Barton T. Jones, MS; and Christie Teigland, PhD.
About Inovalon, Inc.
Inovalon is a leading data analytics technology company that combines advanced data analytics with highly targeted interventions to achieve meaningful impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon's unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, and deep subject matter expertise deliver a seamless, end-to-end platform of technology and nationwide operations that bring the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the unique capabilities to resolve them. Touching more than 540,000 physicians, 220,000 clinical facilities, and more than 140 million Americans, this differentiating combination provides a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, patients, and researchers. For more information visit www.inovalon.com.
SOURCE Inovalon, Inc.